

PYOTT DAVID E I  
Form 4  
October 05, 2012

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
PYOTT DAVID E I

2. Issuer Name and Ticker or Trading Symbol  
ALLERGAN INC [AGN]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)  
2525 DUPONT DRIVE  
(Street)

3. Date of Earliest Transaction (Month/Day/Year)  
10/04/2012

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
Chairman, President and CEO

IRVINE, CA 92612  
(City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V Amount (A) or (D) Price			
Common Stock	09/21/2012		G	V 19,473 D <u>(1)</u>	165,000	D	
Common Stock	09/21/2012		G	V 19,473 A <u>(1)</u>	226,396	I	By Living Trust <sup>(2)</sup>
Common Stock	10/04/2012		S	<u>(3)</u> 206,923 D <u>(4)</u> \$ 93.7388	19,473	I	By Living Trust <sup>(2)</sup>
Common Stock	10/04/2012		M	<u>(3)</u> 119,000 A \$ 30.125	138,473	I	By Living Trust <sup>(2)</sup>

Edgar Filing: PYOTT DAVID E I - Form 4

Common Stock	10/04/2012	M	<u>90,623</u> <sup>(3)</sup>	A	\$ 41.24	229,096	I	By Living Trust <sup>(2)</sup>
Common Stock	10/04/2012	M	<u>101,421</u> <sup>(3)</sup>	A	\$ 41.24	330,517	I	By Living Trust <sup>(2)</sup>
Common Stock	10/04/2012	S	<u>101,421</u> <sup>(3)</sup>	D	\$ 93.7132 <sup>(5)</sup>	229,096	I	By Living Trust <sup>(2)</sup>
Common Stock	10/05/2012	M	<u>307,956</u> <sup>(3)</sup>	A	\$ 41.24	537,052	I	By Living Trust <sup>(2)</sup>
Common Stock	10/05/2012	S	<u>307,956</u> <sup>(3)</sup>	D	\$ 93.724 <sup>(6)</sup>	229,096	I	By Living Trust <sup>(2)</sup>
Common Stock						2,171.2877	I	By 401(k) Trust <sup>(7)</sup>
Common Stock						2,884.9469	I	By Esop Trust <sup>(8)</sup>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount Number Shares
Employee Stock Option (Right to Buy)	\$ 30.125	10/04/2012		M	119,000	<u>(9)</u>	01/30/2013	Common Stock	119,000
Employee Stock	\$ 41.24	10/04/2012		M	90,623	<u>(10)</u>	01/29/2014	Common Stock	90,623

Option  
(Right to  
Buy)

Employee  
Stock

Option (Right to Buy)	\$ 41.24	10/04/2012	M	101,421	<u>(10)</u>	01/29/2014	Common Stock	101,42
-----------------------------	----------	------------	---	---------	-------------	------------	-----------------	--------

Employee  
Stock

Option (Right to Buy)	\$ 41.24	10/05/2012	M	307,956	<u>(10)</u>	01/29/2014	Common Stock	307,95
-----------------------------	----------	------------	---	---------	-------------	------------	-----------------	--------

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
PYOTT DAVID E I 2525 DUPONT DRIVE IRVINE, CA 92612	X		Chairman, President and CEO	

## Signatures

/s/ Matthew J. Maletta, attorney-in-fact for David E.I.  
Pyott

10/05/2012

  Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transfer of 19,473 shares held directly by the reporting person to the David & Julianna Pyott Living Trust.
  - (2) David and Julianna Pyott Living Trust dated June 14, 1999, in which the reporting person has a pecuniary interest and of which the reporting person and his spouse are each trustees.
  - (3) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 20, 2012.  
  
The price reported in column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from \$93.3950 to \$93.9850, inclusive. The reporting person undertakes to provide Allergan, Inc., any security holder of Allergan, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
  - (4) The price reported in column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from \$93.5400 to \$93.9900, inclusive. The reporting person undertakes to provide Allergan, Inc., any security holder of Allergan, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
  - (5) The price reported in column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from \$93.4800 to \$94.3600, inclusive. The reporting person undertakes to provide Allergan, Inc., any security holder of Allergan, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
  - (6) The price reported in column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from \$93.4800 to \$94.3600, inclusive. The reporting person undertakes to provide Allergan, Inc., any security holder of Allergan, Inc., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

## Edgar Filing: PYOTT DAVID E I - Form 4

- (7) Shares allocated to reporting person's SIP account as of reporting date.
- (8) Shares allocated to the reporting person's ESOP account as of reporting date.
- (9) The option becomes exercisable in four equal annual installments beginning January 31, 2004.
- (10) The option becomes exercisable in four equal annual installments beginning January 30, 2005.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.